The Improved Experience You’ve Been Waiting For!
Discover the refreshed menu, enjoy the custom dashboard, and make use of the powerful stock screener to enhance your investment approach.
Explore Now
Based on the Biomerieux SA stock forecast from 0 analysts, the average analyst target price for Biomerieux SA is not available over the next 12 months. Biomerieux SA’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Biomerieux SA is Bullish , which is based on 9 positive signals and 3 negative signals. At the last closing, Biomerieux SA’s stock price was EUR 105.60. Biomerieux SA’s stock price has changed by +0.86% over the past week, +9.54% over the past month and +13.99% over the last year.
No recent analyst target price found for Biomerieux SA
No recent average analyst rating found for Biomerieux SA
Company Overview Biomerieux SA
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA. Address: 376 Chemin De l?Orme, Marcy-l'Étoile, France, 69280 Read Less
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the...Read More
Frequently Asked Questions About Biomerieux SA (BIM:PA) Stock
Stock Target Advisor's fundamental analysis for Biomerieux SA's stock is Bullish .
BIM:PA stock's dividend yield is 0.79%.
Our analysis grades BIM:PA stock's dividend yield at F. This means that BIM:PA stock's dividend yield is above 50% of the stocks in the Diagnostics & Research sector in the PA exchange.
Based on this BIM:PA may be a average dividend stock for its sector.
Unfortunately we do not have enough data on BIM:PA's stock to indicate what its average analyst target is.
BIM:PA stock's Price/Earning ratio is 30.43.
Our analysis grades BIM:PA stock's Price / Earning ratio at D+. This means that BIM:PA stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Diagnostics & Research sector in the PA exchange.
Based on this BIM:PA may be fairly valued for its sector
The last closing price of BIM:PA's stock was EUR 105.60.
The most recent market capitalization for BIM:PA is EUR 12.46B.
Unfortunately we do not have enough analyst data on BIM:PA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Biomerieux SA's stock.
As per our most recent records Biomerieux SA has 13,409 Employees.
Biomerieux SA's registered address is 376 Chemin De l?Orme, Marcy l'Étoile, France, 69280.
You can get more information about it from Biomerieux SA's website at https://www.biomerieux.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Biomerieux SA (BIM:PA) Stock
Stock Target Advisor's fundamental analysis for Biomerieux SA's stock is Bullish .
BIM:PA stock's dividend yield is 0.79%.
Our analysis grades BIM:PA stock's dividend yield at F. This means that BIM:PA stock's dividend yield is above 50% of the stocks in the Diagnostics & Research sector in the PA exchange.
Based on this BIM:PA may be a average dividend stock for its sector.
Unfortunately we do not have enough data on BIM:PA's stock to indicate what its average analyst target is.
BIM:PA stock's Price/Earning ratio is 30.43.
Our analysis grades BIM:PA stock's Price / Earning ratio at D+. This means that BIM:PA stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Diagnostics & Research sector in the PA exchange.
Based on this BIM:PA may be fairly valued for its sector
The last closing price of BIM:PA's stock was EUR 105.60.
The most recent market capitalization for BIM:PA is EUR 12.46B.
Unfortunately we do not have enough analyst data on BIM:PA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Biomerieux SA's stock.
As per our most recent records Biomerieux SA has 13,409 Employees.
Biomerieux SA's registered address is 376 Chemin De l?Orme, Marcy l'Étoile, France, 69280.
You can get more information about it from Biomerieux SA's website at https://www.biomerieux.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BIM:PA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
